Circulating tumor DNA (ctDNA) analysis for improved treatment response assessment and prediction of clinical outcomes in patients with esophageal cancer.

作者
Zexi Allan,Hillary S. Sloane,Karen Harper,Carlos Suhady Cabalag,Maree Pechlivanis,Sasha Witts,Hannah Quinn,Daniel L. Edelstein,David Liu,Nicholas James Clemons
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl): 4077-4077
标识
DOI:10.1200/jco.2025.43.16_suppl.4077
摘要

4077 Background: Despite curative-intent treatment, patients with esophageal cancer experience a high risk of recurrence, and optimal patient management is limited by poor risk stratification and treatment response assessment strategies. ctDNA has demonstrated value as a prognostic biomarker in esophageal cancer; however, improved analytical and clinical performance of ctDNA analysis is necessary to reliably support patient management decisions in clinical practice. Methods: Between September 2017 and June 2023, plasma samples were collected from patients with esophageal cancer before, during, and after standard of care treatment in the routine care setting. In this retrospective analysis, ctDNA testing was performed on a subset of patients using a next-generation tumor-informed assay interrogating up to 50 personalized variants (Haystack MRD, Quest Diagnostics). Results: ctDNA was assessed in 149 samples from 51 patients with stage I-III esophageal adenocarcinoma (n= 40) or squamous cell carcinoma (n= 11). Fifteen patients with clinical follow-up (FU) available at the time of analysis had at least one sample collected after curative-intent treatment [neoadjuvant chemoradiotherapy (nCRT) and surgery (n=10) or definitive CRT (n=5)]. ctDNA was detected (ctDNA+) following curative-intent treatment in 5/15 (33%) patients, all 5 (100%) of whom experienced disease recurrence or were deceased at FU (median time from ctDNA+ result to FU: 14.4 months, range: 0.1-24.5). Of the 10 (67%) patients with no ctDNA detected (ctDNA-) following curative-intent treatment, 7 (70%) were disease-free at FU (median time from ctDNA- result to FU: 46.7 months, range: 6.3-65.5). In the neoadjuvant setting, paired pre- and post-nCRT samples were evaluated in 18 patients, demonstrating ctDNA detection in 18/18 (100%) patients prior to nCRT versus 8/18 (44%) following nCRT. ctDNA positivity following nCRT was strongly associated with poor pathological response (p=0.0026), and ctDNA dynamics observed longitudinally during nCRT served as a robust indicator of response. Of note, one patient experienced metastatic progression during nCRT, discovered at surgery, and ctDNA levels in this patient increased 550-fold while on nCRT. Conclusions: Evaluation of ctDNA using a next-generation tumor-informed platform supports improved response assessment to nCRT as well as accurate risk stratification following curative-intent treatment in patients with esophageal cancer. ctDNA positivity following curative-intent treatment predicted disease recurrence with a lead time of up to 22 months. Additional analyses are ongoing to further validate these findings.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
风来发布了新的文献求助10
1秒前
yuhl完成签到,获得积分10
1秒前
1秒前
2秒前
2秒前
2秒前
2秒前
好吧v完成签到,获得积分20
3秒前
詹詹完成签到,获得积分10
3秒前
3秒前
lulibohan发布了新的文献求助10
4秒前
NexusExplorer的应助被高高冷风采纳,获得10
4秒前
执着怀蝶发布了新的文献求助30
5秒前
5秒前
满意莫茗发布了新的文献求助10
5秒前
冰淇淋灭火器完成签到 ,获得积分10
6秒前
chemhu发布了新的文献求助10
6秒前
6秒前
稳重书双发布了新的文献求助10
6秒前
6秒前
Lucas的应助被ai采纳,获得10
6秒前
梧桐发布了新的文献求助10
7秒前
8秒前
义气的夜安完成签到 ,获得积分10
8秒前
foreknowledge完成签到,获得积分10
8秒前
迷路凌柏发布了新的文献求助10
9秒前
kkkkkk发布了新的文献求助30
9秒前
10秒前
10秒前
11秒前
执着怀蝶完成签到,获得积分20
11秒前
11秒前
琦琦完成签到,获得积分10
12秒前
12秒前
单薄翠绿发布了新的文献求助10
12秒前
12秒前
不与旋覆发布了新的文献求助10
12秒前
12秒前
12秒前
李金成发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178341
求助须知:如何正确求助?哪些是违规求助? 9569073
关于积分的说明 21802629
捐赠科研通 7773188
什么是DOI,文献DOI怎么找? 3432780
关于科研通互助平台的介绍 2556770
邀请新用户注册赠送积分活动 2478298